These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

284 related articles for article (PubMed ID: 30877621)

  • 81. [The mental disorder and obsessive-compulsive spectrum disorders in childhood ].
    Okada T
    Seishin Shinkeigaku Zasshi; 2011; 113(10):992-8. PubMed ID: 22292193
    [No Abstract]   [Full Text] [Related]  

  • 82. [Personality disorders].
    Kiriike N
    Ryoikibetsu Shokogun Shirizu; 2003; (38):469-72. PubMed ID: 12877028
    [No Abstract]   [Full Text] [Related]  

  • 83. Olanzapine addition in obsessive-compulsive disorder refractory to selective serotonin reuptake inhibitors: an open-label case series.
    Weiss EL; Potenza MN; McDougle CJ; Epperson CN
    J Clin Psychiatry; 1999 Aug; 60(8):524-7. PubMed ID: 10485634
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Clinical predictors of long-term outcome in obsessive-compulsive disorder.
    Jakubovski E; Diniz JB; Valerio C; Fossaluza V; Belotto-Silva C; Gorenstein C; Miguel E; Shavitt RG
    Depress Anxiety; 2013 Aug; 30(8):763-72. PubMed ID: 23109056
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Augmentation with cognitive behavioural therapy has superior efficacy to augmentation with risperidone for treating adults with treatment-resistant OCD.
    O'Neill J
    Evid Based Ment Health; 2014 May; 17(2):58-9. PubMed ID: 24713316
    [No Abstract]   [Full Text] [Related]  

  • 86. [A Review and Recommendations of Evidence-Based Treatments for Pediatric Obsessive-Compulsive Disorder].
    Skarphedinsson G; Lauth B; Njardvik U; Ivarsson T
    Laeknabladid; 2016 Apr; 102(4):179-85. PubMed ID: 27197125
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Factors associated with poor response in cognitive-behavioral therapy for pediatric obsessive-compulsive disorder.
    Storch EA; Björgvinsson T; Riemann B; Lewin AB; Morales MJ; Murphy TK
    Bull Menninger Clin; 2010; 74(2):167-85. PubMed ID: 20545494
    [TBL] [Abstract][Full Text] [Related]  

  • 88. [A Case with Multiple Comorbidities of Obsessive-Compulsive and Related Disorders].
    Arikawa A; Mito H; Motoyama M; Yamanishi K; Hayashida K; Maebayashi K; Matsunaga H
    Seishin Shinkeigaku Zasshi; 2015; 117(11):893-901. PubMed ID: 26901889
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Special issue: Update on the nature and treatment of obsessive-compulsive-related disorders.
    Stanley M; Björgvinsson T; Frueh BC
    Bull Menninger Clin; 2010; 74(2):iii-vi. PubMed ID: 20545490
    [No Abstract]   [Full Text] [Related]  

  • 90. Effects of selective serotonin reuptake inhibitors on thought-action fusion, metacognitions, and thought suppression in obsessive-compulsive disorder.
    Besiroglu L; Çetinkaya N; Selvi Y; Atli A
    Compr Psychiatry; 2011; 52(5):556-61. PubMed ID: 21109243
    [TBL] [Abstract][Full Text] [Related]  

  • 91. When to Choose Paroxetine Treatment in Skin-Picking Disorder: A Case Report.
    Arıkan MK; Oba MÇ; İlhan R; Mat MC
    Clin EEG Neurosci; 2023 Mar; 54(2):168-172. PubMed ID: 34994223
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Obsessive-compulsive spectrum disorders: effective treatment with paroxetine.
    Ravindran AV; Lapierre YD; Anisman H
    Can J Psychiatry; 1999 Oct; 44(8):805-7. PubMed ID: 10566112
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Combining Pharmacotherapy with cognitive-behavioral interventions for obsessive-compulsive disorder.
    Cottraux J; Bouvard MA; Milliery M
    Cogn Behav Ther; 2005; 34(3):185-92. PubMed ID: 16201063
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Review of epidemiology, clinical presentation, diagnosis, and treatment of common primary psychiatric causes of cutaneous disease.
    Krooks JA; Weatherall AG; Holland PJ
    J Dermatolog Treat; 2018 Jun; 29(4):418-427. PubMed ID: 29052453
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Obsessive-compulsive disorder.
    Gorman DA; Abi-Jaoude E
    CMAJ; 2014 Aug; 186(11):E435. PubMed ID: 24664647
    [No Abstract]   [Full Text] [Related]  

  • 96. Obsessive-compulsive disorder: strategies for using CBT and pharmacotherapy.
    Storch EA; Merlo LJ
    J Fam Pract; 2006 Apr; 55(4):329-33. PubMed ID: 16608672
    [No Abstract]   [Full Text] [Related]  

  • 97. Predictors of treatment response in pediatric obsessive-compulsive disorder.
    Ginsburg GS; Kingery JN; Drake KL; Grados MA
    J Am Acad Child Adolesc Psychiatry; 2008 Aug; 47(8):868-78. PubMed ID: 18596553
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Addition of cognitive-behaviour therapy for obsessive-compulsive disorder patients non-responding to fluoxetine.
    Kampman M; Keijsers GP; Hoogduin CA; Verbraak MJ
    Acta Psychiatr Scand; 2002 Oct; 106(4):314-9. PubMed ID: 12225499
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Clinical practice. Obsessive-compulsive disorder.
    Jenike MA
    N Engl J Med; 2004 Jan; 350(3):259-65. PubMed ID: 14724305
    [No Abstract]   [Full Text] [Related]  

  • 100. Prevalence and correlates of electroconvulsive therapy delivery in 1001 obsessive-compulsive disorder outpatients.
    Dos Santos-Ribeiro S; Lins-Martins NM; Frydman I; Conceição do Rosário M; Ferrão YA; Shavitt RG; Yücel M; Miguel EC; Fontenelle LF
    Psychiatry Res; 2016 May; 239():145-8. PubMed ID: 27137976
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.